| Questcor Pharma rebounds from after-hours lows, but still -3% on competing drug candidate concerns | - QCOR has moved off of its after-hours low of $50.70, and is now -3% at $52.70 in pre-market trading
- Weakness in QCOR follows news that competitor Retrophin (RTRX) unveiled a new clinical development candidate RE-034, for the treatment of infantile spasms, or West Syndrome, a catastrophic form of epilepsy, and nephrotic syndrome, a devastating condition marked by very high levels of proteinuria
- QCOR's primary product is H.P. Acthar Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications, including the treatment of proteinuria in the nephrotic syndrome (NS) of the idiopathic type, the treatment of acute exacerbations of multiple sclerosis (MS) in adults, the treatment of certain rheumatology related conditions, and the treatment of infantile spasms (IS) in infants and children under two years of age
- Retrophin will host a conference call this morning at 9:00 a.m. ET to discuss development plans for RE-034
- QCOR has a high short-interest, at ~30% of the float, which could add to volatility in the stock around this event
|
